— Know what they know.
Not Investment Advice

CDNA NASDAQ

CareDx, Inc
1W: -7.2% 1M: +24.1% 3M: +63.6% YTD: +86.8% 1Y: +179.5% 3Y: +236.3% 5Y: -56.5%
$35.75
-0.61 (-1.68%)
 
Weekly Expected Move ±18.6%
$23 $30 $37 $44 $51
NASDAQ · Healthcare · Medical - Diagnostics & Research · Alpha Radar Strong Buy · Power 69 · $1.8B mcap · 49M float · 1.85% daily turnover · Short 44% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$1.8B
52W Range11.259-40.47
Volume896,648
Avg Volume908,846
Beta2.43
Dividend
Analyst Ratings
10 Buy 3 Hold 0 Sell
Consensus Buy
Company Info
CEOJohn Walter Hanna Jr.
Employees765
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2014-07-17
Websitecaredx.com
8000 Marina Boulevard
Brisbane, CA 94080
US
415 287 2300
About CareDx, Inc

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Recent Insider Trades

NameTypeSharesPriceDate
Hanna John Walter JR M-Exempt 118,000 $8.20 2026-07-16
Hanna John Walter JR S-Sale 50,000 $36.11 2026-07-16
Hanna John Walter JR S-Sale 68,000 $39.01 2026-07-16
Hanna John Walter JR M-Exempt 118,000 $8.20 2026-07-16
Valantine Hannah M-Exempt 7,606 $20.56 2026-07-16

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms